Arizona State Retirement System cut its position in Hologic, Inc. (NASDAQ:HOLX) by 2.9% during the second quarter, Holdings Channel reports. The institutional investor owned 91,100 shares of the medical equipment provider’s stock after selling 2,700 shares during the period. Arizona State Retirement System’s holdings in Hologic were worth $4,134,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of HOLX. Kovitz Investment Group Partners LLC bought a new stake in shares of Hologic during the second quarter worth $919,000. Stoneridge Investment Partners LLC raised its stake in shares of Hologic by 122.1% in the second quarter. Stoneridge Investment Partners LLC now owns 157,529 shares of the medical equipment provider’s stock worth $7,149,000 after buying an additional 86,615 shares in the last quarter. Global X Management Co. LLC raised its stake in shares of Hologic by 47.9% in the second quarter. Global X Management Co. LLC now owns 11,962 shares of the medical equipment provider’s stock worth $543,000 after buying an additional 3,875 shares in the last quarter. BP PLC raised its stake in shares of Hologic by 240.0% in the second quarter. BP PLC now owns 119,000 shares of the medical equipment provider’s stock worth $5,399,000 after buying an additional 84,000 shares in the last quarter. Finally, Pictet Asset Management Ltd. raised its stake in shares of Hologic by 22.2% in the second quarter. Pictet Asset Management Ltd. now owns 1,938,013 shares of the medical equipment provider’s stock worth $83,936,000 after buying an additional 352,552 shares in the last quarter. 94.43% of the stock is owned by institutional investors.

Shares of Hologic, Inc. (HOLX) opened at 38.19 on Wednesday. The firm has a market cap of $10.71 billion, a price-to-earnings ratio of 14.22 and a beta of 0.90. Hologic, Inc. has a 12-month low of $35.15 and a 12-month high of $46.80. The stock’s 50 day moving average is $43.28 and its 200-day moving average is $42.91.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The business had revenue of $806.10 million for the quarter, compared to analyst estimates of $799.70 million. During the same quarter last year, the firm earned $0.51 EPS. Hologic’s quarterly revenue was up 12.4% compared to the same quarter last year. On average, analysts anticipate that Hologic, Inc. will post $2.01 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Hologic, Inc. (HOLX) Shares Sold by Arizona State Retirement System” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/16/hologic-inc-holx-shares-sold-by-arizona-state-retirement-system.html.

A number of analysts have recently weighed in on the stock. BidaskClub lowered shares of Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Barclays PLC reaffirmed an “equal weight” rating and issued a $51.00 price target (down from $53.00) on shares of Hologic in a research note on Wednesday, August 9th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $45.00 target price (down from $50.00) on shares of Hologic in a report on Wednesday, August 9th. Zacks Investment Research upgraded shares of Hologic from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Finally, Deutsche Bank AG dropped their target price on shares of Hologic from $51.00 to $49.00 and set a “buy” rating on the stock in a report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the company’s stock. Hologic has a consensus rating of “Buy” and a consensus price target of $48.64.

In related news, VP Karleen Marie Oberton sold 4,704 shares of Hologic stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $45.19, for a total transaction of $212,573.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Lawrence M. Levy sold 9,193 shares of Hologic stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $42.93, for a total transaction of $394,655.49. Following the transaction, the director now directly owns 46,206 shares in the company, valued at approximately $1,983,623.58. The disclosure for this sale can be found here. Insiders have sold a total of 51,551 shares of company stock worth $2,244,458 in the last three months. 0.79% of the stock is owned by insiders.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.